7200-25-1

Basic information

• Product Name: DL-Arginine
• Synonyms: DL-ARGININE;DL-1-AMINO-4-GUANIDINO-N-VALERIC ACID;DL-2-AMINO-5-GUANIDINOPENTANOIC ACID;DL-2-AMINO-5-GUANIDINOVALERIC ACID;H-DL-ARG-OH;DL-Arg-OH;ACETYL-DL-ARGININE, N-(P);ARGININE, D/L-(RG)
• CAS NO: 7200-25-1
• Molecular Formula: C₆H₁₄N₄O₂
• Molecular Weight: 174.2
• EINECS: 230-571-3
• Product Categories: Arginine [Arg, R];Amino Acids
• Mol File: 7200-25-1.mol
• Article Data: 129

Chemical Properties

• Melting Point: 228-233 °C (dec.)
• Boiling Point: 305.18°C (rough estimate)
• Flash Point: 201.2℃
• Appearance: White powder
• Density: 1.46
• Refractive Index: 1.6700 (estimate)
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 2.49±0.24(Predicted)
• Water Solubility: 155 g/L (20 ºC)
• Sensitive: Air Sensitive
• BRN: 1725411
• CAS DataBase Reference: DL-Arginine(CAS DataBase Reference)
• NIST Chemistry Reference: DL-Arginine(7200-25-1)
• EPA Substance Registry System: DL-Arginine(7200-25-1)

Safety Data

• Hazard Codes: Xi
• Statements: 36
• Safety Statements: 26-39
• WGK Germany: 3
• F: 10-23
• TSCA: Yes
• Hazardous Substances Data: 7200-25-1(Hazardous Substances Data)

Usage

Chemical Properties

white powder

Uses

DL-Arginine is used in the synthesis of creatine and polyamines. DL-Arg is used in physicochemical analysis of amino acid complexation dynamics and crystal structure formations.

Definition

ChEBI: An alpha-amino acid that is glycine in which the alpha-is substituted by a 3-guanidinopropyl group.

InChI:InChI=1/C6H14N4O2/c7-4(5(11)12)2-1-3-10-6(8)9/h4H,1-3,7H2,(H,11,12)(H4,8,9,10)/t4-/m0/s1

Upstream product

• 6453-58-3 N-α-benzoyl-DL-arginine 
• 4480-62-0 5-Guanidino-2-(4-methoxy-benzyloxycarbonylamino)-pentanoic acid 
• 1234-35-1 2-Benzyloxycarbonylamino-5-guanidino-pentanoic acid 
• 123-91-1 1,4-dioxane 
• 50-01-1 guanidine hydrochloride 
• 108-95-2 phenol 
• 110-89-4 piperidine 
• 70-54-2 2,6-diaminocaproic acid 
• 2440-60-0 2-methyl-isourea 
• 4668-32-0 N^α-Benzoylornithine 
• 744-46-7 N-benzoylglycyl-L-arginine 
• 157-06-2 D-arginine 

Downstream Products

• 70-26-8 D-ornithine 
• 74-79-3 L-arginine 
• 57-13-6 urea 
• 61057-57-6 5-Guanidino-2-(2-p-tolyloxy-acetylamino)-pentanoic acid 
• 61057-62-3 2-[2-(4-Acetyl-phenoxy)-acetylamino]-5-guanidino-pentanoic acid 
• 61057-66-7 2-[2-(4-Acetylamino-phenoxy)-acetylamino]-5-guanidino-pentanoic acid 
• 107759-00-2 opt.-inactive !-N^α-(N-acetyl-phenylalanyl)-arginine 
• 4307-78-2 N^α-dansyl-L-arginine 
• 4307-78-2 2-(5-Dimethylamino-naphthalene-1-sulfonylamino)-5-guanidino-pentanoic acid 
• 97801-55-3 2-(4-Fluoro-benzenesulfonylamino)-5-guanidino-pentanoic acid 
• 157-06-2 D-arginine 
• 53123-88-9 sirolimus 

Relevant articles and documents

RNA VIRUS-DERIVED PEPTIDES WITH MODIFIED SIDE CHAINS

The present invention provides a RNA virus-derived peptides with modified side chains, wherein the side chains of the RNA virus-derived peptide are modified by altering the side-chain length or charges thereof such that the RNA virus-derived peptide has a high binding affinity for viral RNA and an high cellular uptake capability. The present invention also provides a composition for inhibiting RNA virus wherein the RNA virus-derived peptide can effectively inhibit viral self-replication and treat related diseases by its high affinity for viral RNA. A drug delivery carrier is also provided, wherein the RNA virus-derived peptides can carry desired drugs to the intracellular target due to its cellular uptake capability and thereby enhances the drug-delivery and treating efficiency.

New polypeptides inducing apoptosis and uses thereof

The present invention concerns a polypeptide comprising the sequence X1WX2X3X4RX5X6X7 X8 X9, and derivatives thereof, wherein X1 is an amino acid selected in the group consisting in histidinc (H), tyrosinc (Y), aspartic acid (D), glutamine (Q), and leucine (L), preferably histidine (H) or tyrosine (Y); X2 is a polar amino acid, charged or not, and selected in the group consisting in serine (S) threonine (T), lysine (K), arginine (R), asparagine (N), aspartic acid (D), cysteine (C), glycine (G), glutamine (Q), histidine (H), and glutamic acid (E); X3 is a polar amino acid, charged or not, and selected in the group consisting in serine (S), threonine (T), asparagine (N), cysteine (C), histidine (H), leucine (L), tyrosine (Y), alanine (A), and isoleucine (1); X4 is an amino acid selected in the group consisting in threonine (T), arginine (R), asparagine (N), alanine (A), isoleucine (I), leucine (L), methionine (M), phenylalanine (F), tryptophane (W), valine (V) and tyrosine; X5 is an amino acid selected in the group consisting in leucine (L), methionine (M), isoleucine (I), tryptophane (W), tyrosine (Y), histidine (H), glutamine (Q), lysine (K), and arginine (R); X6 is an amino acid selected in the group consisting in leucine (L), and glutamic acid (E); X7 is an amino acid selected in the group consisting in cysteine (C), asparagine (N), alanine (A), tyrosine (Y), serine (S), glutamine (Q), and proline (P); X8 is a hydrophobic amino acid selected in the group consisting in alanine (A), isoleucine (I), leucine (L), methionine (M), phenylalanine (F), tryptophane (W), valine (V) and tyrosine; and X9 is a threonine or an hydrophobic amino acid selected in the group consisting in alanine (A), isoleucine (I), leucine (L), methionine (M), phenylalanine (F), tryptophane (W), valine (V) and tyrosine.

Nucleic acids for expressing a polynucleotide of interest in mammalian cancer cells

The invention relates to regulatory polynucleotides derived (i) from rat and human AFP promoter sequences and (ii) from rat and human HIP/PAPI promoter sequences, which regulatory polynucleotides are useful for expressing nucleic acids of interest specifically in mammalian cancer cells, including mammalian cancer liver cells.